Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, founded in 2012. The company specializes in developing biocatalysts for the fermentation of complex chemical compounds, such as flavors, fragrances, active pharmaceutical ingredients (APIs), pigments, and additives. Utilizing its innovative, patent-pending high-throughput screening technology, Biosyntia accelerates the development of these biocatalysts, aiming to enhance efficiency and reduce production costs. By focusing on biocatalysis, the company offers a more sustainable alternative to traditional chemical synthesis, significantly lowering environmental impacts. Biosyntia collaborates with manufacturers to create tailored fermentation processes that promote greener manufacturing practices in the fine chemicals industry.
Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants, leveraging its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to manipulate gene expression in plants while preserving their DNA. This innovative approach enables the regulation of various growth processes, including germination, flowering, and overall plant growth, as well as effective weed control. By focusing on the use of natural molecules, Micropep aims to provide sustainable solutions for agricultural challenges.
GFBiochemicals is the only company to produce levulinic acid at commercial scale directly from biomass. In 2008, a group of biobased chemical experts saw the significant potential of levulinic acid to replace petroleum-based products across a range of market sectors. GFBiochemicals was founded to develop the production technology needed for this revolution in chemicals and biofuels. GFBiochemicals demonstrated these breakthrough technologies in the Caserta plant, in partnership with the University of Pisa and the Polytechnic University of Milan. This commercial-scale plant was retrofitted with new conversion, recovery and purification technology.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
Home Biosciences is a European venture builder focused on the biotechnology sector. The company aims to facilitate scientific breakthroughs by employing an asset-centric operating model. It provides essential funding and operational support, allowing project teams to concentrate on their core objectives. By assembling the appropriate expertise and structure, Home Biosciences helps to foster the growth of sustainable biotech ventures.
Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.
Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers specialized cell analysis systems that facilitate the discovery of new cell strains and molecules, aiding scientists in screening for and isolating rare biological variants. Their products serve various applications, including research, therapeutic development, bioproduction, and diagnostics. By providing collaborative research and development services, Sphere Fluidics aims to help clients enhance efficiency, reduce costs, and accelerate advancements in biological and biopharmaceutical discovery.
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.
Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Operator of a biopharmaceutical company intended to discover and develop therapies that slow or stop the progression of neurodegenerative diseases. The company engages in identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia, and Parkinson's, enabling people suffering from neurodegenerative diseases to access suitable therapeutics for fast recovery.
Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants, leveraging its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to manipulate gene expression in plants while preserving their DNA. This innovative approach enables the regulation of various growth processes, including germination, flowering, and overall plant growth, as well as effective weed control. By focusing on the use of natural molecules, Micropep aims to provide sustainable solutions for agricultural challenges.
Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.
Borea Therapeutics is advancing a new generation of gene therapies that would enable the targeting of specific tissues and cells.
Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.
Myricx Bio is a drug discovery company based in Stevenage, United Kingdom, that specializes in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT). Founded in 2019, the company focuses primarily on oncology while also exploring applications in other diseases such as inflammatory conditions, epilepsy, and Alzheimer’s disease. By targeting N-myristoyl transferase, Myricx Bio aims to unlock new therapeutic potentials, providing precision medicines that can specifically kill cancer cells and address viral infections. Through its innovative approach, the company seeks to deliver effective treatments for a diverse range of health conditions.
Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
PinCell is a biotech company focused on the research of therapeutic molecules based on new targets related to the pathomechanisms of inflammatory and neoplastic skin diseases.
Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.
Redx Pharma is a UK-based drug discovery and development company founded in 2010, focusing on creating innovative small molecule drugs aimed at treating cancer, fibrosis, and other unmet medical needs. The company is advancing several key drug candidates, including RXC004, a porcupine inhibitor in Phase I clinical trials for various cancers, and a ROCK inhibitor targeting inflammatory diseases related to fibrosis. Other notable developments include a Rho-associated protein kinase 2 inhibitor for diabetic nephropathy and idiopathic pulmonary fibrosis, along with a Pan-RAF inhibitor and SHP2 for cancer treatment. Additionally, Redx Pharma collaborates with Jazz Pharmaceuticals to explore drug candidates targeting the Ras/Raf/MAP kinase pathway. The company operates through three subsidiaries: Redx Oncology, Redx Anti-Infectives, and Redx Immunology, and has established partnerships with major pharmaceutical firms and the NHS to enhance its research and development efforts.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.
DMC Biotechnologies, Inc. is a biotechnology company based in Boulder, Colorado, focused on developing bio-based products through microbial fermentation technology. The company specializes in the production of specialty chemicals, flavors, fragrances, nutraceuticals, and pharmaceuticals. By utilizing Dynamic Metabolic Control technology, DMC aims to streamline the production process, reducing both costs and development timelines from discovery to commercial viability. Founded in 2014, DMC Biotechnologies is dedicated to creating sustainable manufacturing solutions that utilize lower energy and resources, contributing to a more sustainable economy.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Microphyt, founded in 2007 and headquartered in Baillargues, France, specializes in the research, development, production, and marketing of natural algae-based products. The company focuses on microalgae and other photosynthetic microorganisms, targeting sectors such as beauty care, food, health, and energy. Its offerings include dietary supplements and products aimed at promoting weight loss and enhancing brain health. Utilizing industrial-scale cultivation techniques, Microphyt preserves the integrity of microalgae cells to produce biomass and extracts in commercial quantities. This approach enables the healthcare industry to meet the growing demand for innovative personal care and food products.
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.
Comet Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. It specializes in developing novel small-molecule treatments targeting various diseases, particularly orphan neurological disorders. The company's core innovation is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism. This therapeutic approach enables healthcare providers to address significant unmet medical needs in the treatment of these complex conditions.
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.
Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.
Afyren is a sustainable chemistry company based in Saint-Beauzire, France, focused on the valorization of non-food biomass to develop environmentally friendly alternatives to petroleum-based products. Founded in 2012, the company employs innovative biotechnological processes using natural microorganisms to produce a range of bio-sourced organic acids and a high-value fertilizer. Its services extend to microbiology and bioprocess engineering, supporting various sectors including pharmaceuticals, cosmetics, green chemistry, and biopolymers. Afyren's approach aligns with the principles of a circular, low-carbon economy, emphasizing the importance of waste reduction and sustainable resource utilization.
Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, founded in 2012. The company specializes in developing biocatalysts for the fermentation of complex chemical compounds, such as flavors, fragrances, active pharmaceutical ingredients (APIs), pigments, and additives. Utilizing its innovative, patent-pending high-throughput screening technology, Biosyntia accelerates the development of these biocatalysts, aiming to enhance efficiency and reduce production costs. By focusing on biocatalysis, the company offers a more sustainable alternative to traditional chemical synthesis, significantly lowering environmental impacts. Biosyntia collaborates with manufacturers to create tailored fermentation processes that promote greener manufacturing practices in the fine chemicals industry.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
EryDel S.p.A., based in Urbino, Italy, specializes in the production and commercialization of innovative drug delivery systems utilizing autologous erythrocytes, or red blood cells. Founded in 2007, the company has developed patented technology that allows for the efficient loading of red blood cells with various therapeutic agents, including drugs and proteins. This approach enables a gradual release of these agents into the patient's body, enhancing treatment efficacy while minimizing side effects. The technology is particularly beneficial for managing chronic conditions, offering a potential alternative to daily treatments through monthly transfusions of specially loaded blood. EryDel's offerings include a red cell loader and disposable kits to support the drug delivery process. The company's solutions have been tested in treating Inflammatory Bowel Diseases (IBDs) such as ulcerative colitis and Crohn's disease, and it aims to improve the management of other rare diseases through its innovative therapies.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants, leveraging its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to manipulate gene expression in plants while preserving their DNA. This innovative approach enables the regulation of various growth processes, including germination, flowering, and overall plant growth, as well as effective weed control. By focusing on the use of natural molecules, Micropep aims to provide sustainable solutions for agricultural challenges.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.
Breath Therapeutics GmbH, based in Munich, Germany, with an additional office in Menlo Park, California, develops innovative drug-aerosol therapeutics aimed at treating bronchiolitis obliterans syndrome and other severe respiratory diseases. Founded in 2016 and now a subsidiary of Zambon S.p.A., the company focuses on combining novel formulations of existing drugs with advanced inhalation technologies. Their products include a liposomal formulation of cyclosporine A designed for inhalation, paired with a high-performance nebulizer that optimizes drug delivery. This approach allows for rapid delivery of high drug concentrations directly to the lungs, enhancing the efficacy of treatments while reducing systemic exposure. Breath Therapeutics aims to address significant unmet medical needs in rare pulmonary conditions through its targeted inhalation therapies.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
myTomorrows is a healthcare information platform that facilitates access to innovative drugs in development for patients and physicians who are often excluded from clinical trials. The company focuses on areas with significant unmet medical needs, including oncology, neurology, psychiatry, and rare diseases. By identifying promising treatments and gathering relevant information, myTomorrows informs both patients and healthcare providers about available drug options. The platform enables users to request access to these innovative therapies, thereby improving the chances for patients to receive potentially life-saving treatments that are otherwise difficult to obtain.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.
MedDay is an international biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company is focused on creating disease-modifying therapies that aim to repair and protect the nervous system. By investigating brain metabolism, MedDay seeks to address significant unmet medical needs and improve patient care for those affected by these disorders. The promising outcomes from their clinical trials motivate the company to continue exploring innovative treatment options, ultimately striving to enhance the quality of life for patients and their caregivers in the healthcare community.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, focused on drug discovery and development for acute and chronic viral infections. Founded in 2014 by a group of scientists from the Infectiology Research Center, the company has established a unique platform to identify intracellular therapeutic targets and molecules, particularly for human pathogens. ENYO Pharma is developing treatments for significant viral infections, with ongoing programs targeting chronic hepatitis B and severe influenza. Its lead compound, EYP001, is designed to modulate FXR and reduce viral replication, while EYP002 is currently undergoing preclinical studies. The company aims to advance its pipeline into Phase II clinical trials and collaborates closely with research institutions to leverage innovative therapeutic strategies. ENYO Pharma is committed to addressing unmet medical needs in infectious and metabolic diseases, positioning itself as a leader in antiviral therapies.
ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.
Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.
Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.
myTomorrows is a healthcare information platform that facilitates access to innovative drugs in development for patients and physicians who are often excluded from clinical trials. The company focuses on areas with significant unmet medical needs, including oncology, neurology, psychiatry, and rare diseases. By identifying promising treatments and gathering relevant information, myTomorrows informs both patients and healthcare providers about available drug options. The platform enables users to request access to these innovative therapies, thereby improving the chances for patients to receive potentially life-saving treatments that are otherwise difficult to obtain.
Avantium is a technology company based in Amsterdam, specializing in advanced high-throughput research and development for the energy, chemicals, and pharmaceutical sectors. It employs proprietary technology that accelerates and reduces the costs associated with developing new products and processes. Avantium's innovative approach to experiment design and data analysis enhances its success rate in delivering effective solutions. The company has successfully collaborated with over 70 global clients, showcasing the commercial viability of its services. Avantium focuses on two primary areas: developing biofuels and bio-based chemicals, as well as new crystal forms of patented drugs. Its business model includes a strong emphasis on expanding its patent portfolio and establishing partnerships that add value. Additionally, Avantium operates through segments such as R&D Solutions, Renewable Chemistries, and Renewable Polymers, with the R&D Solutions segment generating the majority of its revenue. The company is supported by a team of experts in various fields, including catalysis, organic chemistry, and software development, who work closely with partner organizations to drive innovation in sustainable chemistry.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
ProQR Therapeutics N.V. is a biopharmaceutical company focused on the discovery and development of RNA-based therapeutics aimed at treating genetic disorders. The company is advancing several key product candidates, including sepofarsen, currently in a phase II/III trial for Leber’s congenital amaurosis type 10, and QR-421a, which is in a phase 1/2 trial for Usher syndrome type 2 and non-syndromic retinitis pigmentosa. Additionally, QR-1123 is in a phase 1/2 trial for autosomal dominant retinitis pigmentosa, while QR-504a is undergoing its first clinical trial for Fuchs endothelial corneal dystrophy. ProQR Therapeutics has established collaboration agreements with prominent institutions such as General Hospital Corporation and Radboud University Medical Center. Founded in 2012, the company is headquartered in Leiden, the Netherlands.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.
Auris Medical is a biopharmaceutical company focused on developing innovative therapies for the treatment and prevention of disorders affecting the inner ear and central nervous system. Its advanced clinical programs include Keyzilen for acute inner ear tinnitus and AM-111 for acute inner ear hearing loss. The company is also working on AM-125, which is in Phase 2 trials for the intranasal treatment of acute peripheral vertigo, and AM-201, in Phase 1b trials aimed at preventing side effects associated with antipsychotic medications. Additionally, Auris Medical is developing AM-102 for tinnitus treatment. The company collaborates with academic institutions and other entities such as INSERM and Xigen S.A. to enhance its product offerings, including drug delivery devices for local administration to the inner ear. Founded in 1998, Auris Medical is headquartered in Hamilton, Bermuda.
MedDay is an international biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company is focused on creating disease-modifying therapies that aim to repair and protect the nervous system. By investigating brain metabolism, MedDay seeks to address significant unmet medical needs and improve patient care for those affected by these disorders. The promising outcomes from their clinical trials motivate the company to continue exploring innovative treatment options, ultimately striving to enhance the quality of life for patients and their caregivers in the healthcare community.
ProQR Therapeutics N.V. is a biopharmaceutical company focused on the discovery and development of RNA-based therapeutics aimed at treating genetic disorders. The company is advancing several key product candidates, including sepofarsen, currently in a phase II/III trial for Leber’s congenital amaurosis type 10, and QR-421a, which is in a phase 1/2 trial for Usher syndrome type 2 and non-syndromic retinitis pigmentosa. Additionally, QR-1123 is in a phase 1/2 trial for autosomal dominant retinitis pigmentosa, while QR-504a is undergoing its first clinical trial for Fuchs endothelial corneal dystrophy. ProQR Therapeutics has established collaboration agreements with prominent institutions such as General Hospital Corporation and Radboud University Medical Center. Founded in 2012, the company is headquartered in Leiden, the Netherlands.
Flexion Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions. Based in Burlington, Massachusetts, it offers ZILRETTA, an intra-articular injection specifically designed for managing osteoarthritis pain in the knee. The company is also developing FX201, a gene therapy aimed at promoting the production of an anti-inflammatory protein for knee osteoarthritis pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Since its founding in 2007, Flexion Therapeutics has collaborated with pharmaceutical and biotechnology firms to advance its drug candidates through clinical trials, thereby enhancing the therapeutic portfolios of its partners.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.
Creabilis SA is a clinical stage biotechnology company based in Luxembourg City, specializing in the research and development of new drugs for dermatology and inflammatory diseases. Founded in 2003, the company has developed a diverse pipeline of clinical and pre-clinical drug candidates, addressing significant unmet medical needs in skin disorders. Notable products in its portfolio include CT327, a TrkA kinase inhibitor aimed at treating psoriasis and atopic dermatitis; CT340, which targets both TrkA and MAP2K3 kinases for inflammatory arthritis and pain; and CT637, an HMGB1 antagonist for various inflammatory conditions. Creabilis also engages in early-stage projects to explore additional treatment options. With research offices in Ivrea, Italy, and development operations in Canterbury, United Kingdom, the company aims to market its innovative therapies either independently or through partnerships.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Omthera Pharmaceuticals, Inc. is a specialty pharmaceuticals company dedicated to the clinical development of new therapies for dyslipidemia, a condition characterized by elevated triglyceride levels that increases the risk of cardiovascular disease. The company is led by a team of experienced professionals in the field of lipid disorders, focusing on creating innovative treatments aimed at improving the health and quality of life for millions of affected patients. By concentrating on this specific area of healthcare, Omthera aims to address the unmet medical needs of individuals suffering from dyslipidemia and contribute to better management of cardiovascular risk.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
TME Pharma is a biotechnology company based in Berlin, Germany, focused on developing innovative therapeutics for cancer treatment. The company utilizes its proprietary Spiegelmer platform, which involves biostable aptamers and mirror image nucleic acids, to create a pipeline of clinical-stage product candidates. Its lead drug candidate, NOX-A12, is being investigated as a combination therapy for various cancer types, including metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. TME Pharma is also advancing NOX-E36, which has completed Phase IIa trials for diabetic nephropathy. The company has established partnerships, including a collaboration with Merck & Co. to explore the efficacy of NOX-A12 in combination with Keytruda in patients with metastatic solid tumors. Founded in 1997, TME Pharma continues to advance its mission of developing novel treatments for serious medical conditions.
Omthera Pharmaceuticals, Inc. is a specialty pharmaceuticals company dedicated to the clinical development of new therapies for dyslipidemia, a condition characterized by elevated triglyceride levels that increases the risk of cardiovascular disease. The company is led by a team of experienced professionals in the field of lipid disorders, focusing on creating innovative treatments aimed at improving the health and quality of life for millions of affected patients. By concentrating on this specific area of healthcare, Omthera aims to address the unmet medical needs of individuals suffering from dyslipidemia and contribute to better management of cardiovascular risk.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
Flexion Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions. Based in Burlington, Massachusetts, it offers ZILRETTA, an intra-articular injection specifically designed for managing osteoarthritis pain in the knee. The company is also developing FX201, a gene therapy aimed at promoting the production of an anti-inflammatory protein for knee osteoarthritis pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Since its founding in 2007, Flexion Therapeutics has collaborated with pharmaceutical and biotechnology firms to advance its drug candidates through clinical trials, thereby enhancing the therapeutic portfolios of its partners.
EOS is a biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.EOS S.p.A. was founded in June 2006 by Silvano Spinelli, Gabriella Camboni, and Ennio Cavalletti along with Jacques Theurillat. Company’s operations were seed and further financed by founders and by Sofinnova Partners since its inception. EOS is a privately held organization headquartered in Via Monte di Pietà, 1/A, Milano, Italy.
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.
Creabilis SA is a clinical stage biotechnology company based in Luxembourg City, specializing in the research and development of new drugs for dermatology and inflammatory diseases. Founded in 2003, the company has developed a diverse pipeline of clinical and pre-clinical drug candidates, addressing significant unmet medical needs in skin disorders. Notable products in its portfolio include CT327, a TrkA kinase inhibitor aimed at treating psoriasis and atopic dermatitis; CT340, which targets both TrkA and MAP2K3 kinases for inflammatory arthritis and pain; and CT637, an HMGB1 antagonist for various inflammatory conditions. Creabilis also engages in early-stage projects to explore additional treatment options. With research offices in Ivrea, Italy, and development operations in Canterbury, United Kingdom, the company aims to market its innovative therapies either independently or through partnerships.
Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for acute and chronic liver diseases, addressing significant unmet medical needs. The company's lead product, OCR-002, is an ammonia scavenger available in both intravenous and oral formulations, specifically targeting hyperammonemia. Ocera recently completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. The company is planning to engage with the FDA to explore potential development pathways for its intravenous program later this year.
Fovea Pharmaceuticals is a French biopharmaceutical company based in Paris, specializing in the discovery and development of drugs for ocular diseases. Founded in 2005, the company focuses on addressing various eye conditions, including allergic conjunctivitis, diabetic macular edema, and retinitis pigmentosa. Its product portfolio includes FOV1101 Prednisporin for allergic conjunctivitis, a proprietary plasma kallikrein-kinin inhibitor known as FOV2302 for hereditary angioedema, FOV2304 for diabetic macular edema, and FOV2501, an intravitreal formulation targeting retinitis pigmentosa and potentially dry age-related macular degeneration. As of October 30, 2009, Fovea operates as a subsidiary of Sanofi.
PregLem is a Swiss-based biopharmaceutical company focused on the development and commercialization of innovative drugs specifically for women's reproductive health. The company aims to address unmet medical needs in this field by creating advanced therapies that enhance the quality of care for women. Through its specialized approach, PregLem is committed to improving treatment options and outcomes for various reproductive health conditions.
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.
Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).
PregLem is a Swiss-based biopharmaceutical company focused on the development and commercialization of innovative drugs specifically for women's reproductive health. The company aims to address unmet medical needs in this field by creating advanced therapies that enhance the quality of care for women. Through its specialized approach, PregLem is committed to improving treatment options and outcomes for various reproductive health conditions.
TME Pharma is a biotechnology company based in Berlin, Germany, focused on developing innovative therapeutics for cancer treatment. The company utilizes its proprietary Spiegelmer platform, which involves biostable aptamers and mirror image nucleic acids, to create a pipeline of clinical-stage product candidates. Its lead drug candidate, NOX-A12, is being investigated as a combination therapy for various cancer types, including metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. TME Pharma is also advancing NOX-E36, which has completed Phase IIa trials for diabetic nephropathy. The company has established partnerships, including a collaboration with Merck & Co. to explore the efficacy of NOX-A12 in combination with Keytruda in patients with metastatic solid tumors. Founded in 1997, TME Pharma continues to advance its mission of developing novel treatments for serious medical conditions.
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.
Movetis NV is a pharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting gastrointestinal (GI) disorders. The company addresses a range of conditions, including severe chronic constipation, ascites, and pediatric reflux, as well as severe GI motility disorders like refractory gastro-oesophageal reflux disease. Its lead product, Resolor, is specifically designed for the symptomatic treatment of chronic constipation in women, with ongoing research for its efficacy in males and children, as well as in cases of opioid-induced constipation and post-operative ileus. Movetis is also developing M0002, currently in Phase II trials for treating ascites, and M0003, which is set to enter Phase II development for symptomatic relief of heartburn and regurgitation in patients unresponsive to proton pump inhibitors. Additionally, the company has two prioritized compounds from its preclinical portfolio and maintains partnerships with universities in Ghent, Leuven, and Rotterdam. Founded in 2006, Movetis is based in Turnhout, Belgium.
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.
Ablynx NV is a clinical biopharmaceutical company based in Ghent, Belgium, that specializes in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments. The company focuses on addressing serious human diseases, including inflammation, hematology, oncology, and respiratory conditions. Ablynx has a diverse pipeline with approximately 25 projects, featuring five Nanobodies currently in clinical development. Notable clinical programs include caplacizumab for acquired thrombotic thrombocytopenic purpura, ALX-0171 for respiratory syncytial virus infection, and Vobarilizumab for rheumatoid arthritis and systemic lupus erythematosus. Other ongoing trials involve treatments for psoriasis, solid tumors, chronic kidney diseases, and bone-loss related disorders. Ablynx has established collaboration agreements with several major pharmaceutical companies to advance its research and development efforts. Founded in 2001, Ablynx was formerly known as MatchX and rebranded in 2002. The company operates as a subsidiary of Sanofi.
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.
Lectus Therapeutics Limited is a UK-based pharmaceutical company dedicated to drug discovery and development, specializing in next-generation ion channel modulators. The company aims to create a robust pipeline of first-in-class therapeutics, primarily targeting pain management and urinary bladder disorders. Utilizing proprietary proteomics technology, Lectus Therapeutics focuses on developing innovative treatments for various conditions, including angina, asthma, and epilepsy, alongside its core areas of interest. Through its commitment to advancing ion channel therapeutics, the company seeks to address unmet medical needs in the pharmaceutical landscape.